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A denervated heart coupled to a periphery previously 
exposed to high catecholamine levels provides a unique 
model to study adrenoceptor physiology. Six orthotopic 
transplant patients (1.3 2 0.8 years postoperative) were age 
matched with six atropine-treated normal subjects. Simul- 
taneous two-dimensionally targeted left ventricular echo- 
cardiograms and calibrated carotid pulse tracings were 
recorded. Left ventricular contractility was assessed with 
use of heart rate- and load-independent end-systolic in- 
dexes. Studies were performed at baseline and during 
dobutamine infusion with and without beta-adrenergic 
blockade with use of propranolol; effects were assessed 
during afterload changes generated by the alpha, agonist 
methoxamine. 
There were no differences in baseline contractility or 
reserve between transplant patients and normal subjects. 
The heart rate response to dobutamine was greater for 
transplant patients (p < 0.001). In both groups, the positive 
inotropic and chronotropic effects of dobutamine were 
ablated by propranolol. Dobutamine plus propranolol (un- 
opposed alpha, effect) did not change mean systemic pres- 
sure in transplant patients while markedly raising mean 
systemic pressures in normal subjects (36 f 18 mm Hg; p < 
0.001). In addition, during initial challenge with methox- 
amine, the transplant patients required 60% more alpha, 
agonist than did the normal subjects (p < 0.001) to obtain 
a pressor effect. 
In summary, transplant patients who were previously in 
severe heart failure have normal left ventricular inotropic 
response to beta, activation and blockade, exaggerated 
chronotropic response to dobutamine and reduced sensitiv- 
ity to stimulation with alpha,-adrenoceptor agonists. These 
findings are consistent with a differential response of 
adrenoceptors to long-term stimulation after cardiac trans- 
plantation. 
(J Am Co11 Cardiol1989;14:1229-38) 
Orthotopic cardiac transplantation represents a unique phys- 
iologic model for the assessment of adrenoceptor function in 
humans. In such cases, a denervated “healthy” heart is 
attached to a peripheral vascular bed that has previously 
been exposed to low cardiac output and markedly elevated 
plasma catecholamine concentrations (l-5). With transplan- 
tation, normal levels of cardiac output are usually restored. 
However, little is known about the effects of improved blood 
flow on peripheral vascular responses to adrenoceptor ago- 
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nists in these patients. To explore this issue, load- 
independent sensitive indexes of left ventricular contractility 
in conjunction with systemic blood pressure measurements 
and vascular resistance calculations (5-10) were used to 
establish the myocardial and peripheral effects of adrenocep- 
tor stimulation and blockade in transplant patients and 
normal subjects. 
Specijically, three agents were used as pharmacologic 
probes: 1) dobutamine, a catecholamine with beta,, beta, 
and alpha, agonist effects; 2) methoxamine, a catecholamine 
with only alpha,-agonist actions; and 3) propranolol, a 
nonspecific beta-adrenoceptor antagonist. 
Methods 
Study patients. The study group was composed of six 
men who underwent orthotopic cardiac transplantation at 
Harefield Hospital, Harefield, Middlesex, England. Before 
transplantation, all patients had long-standing congestive 
heart failure and were in New York Heart Association 
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functional class IV. No one was treated with alpha,- 
adrenergic receptor blocking agents either before or after 
operation and all had taken no anti-hypertensive therapy for 
21 month. At the time of operation, the subjects ranged in 
age from 41 to 53 years (mean ? SD 49 ? 5). The donor 
hearts were between 18 and 39 years of age (mean 25 + 7). 
The interval from transplant surgery to study was 1.3 ? 0.8 
years (range 0.6 to 2.8). During this period, the patients had 
an average of 1.2 ? 1.0 episodes of transplant rejection. No 
patient had evidence of rejection by endomyocardial biopsy 
performed within 7 days of study nor did any patient have 
evidence for accelerated atherosclerosis on coronary arteri- 
ography. Immunosuppressive therapy included azathioprine 
in six cases, 10 to 15 mg/day of prednisone in five cases and 
cyclosporine in two cases. Portions of the transplant pa- 
tients’ data on left ventricular contractile reserve have been 
reported previously (11). 
Comparisons of contractility data were performed with 
data acquired from six normal subjects matched for donor 
heart age. Comparisons of peripheral vascular hemodynam- 
its were made using these six normal subjects as well as six 
additional normal subjects matched to the cardiac transplant 
recipients’ ages. The protocol used to study the cardiac 
transplant patients met the criteria for human investigation 
previously established at Harefield Hospital. The protocol 
used for the normal control subjects was approved by the 
Committee on Human Protection from Research Risks of 
The University of Chicago Medical Center. In all cases, 
informed consent was obtained. 
Experimental design. The transplant patients and normal 
subjects were studied with use of similar protocols. Simul- 
taneous recordings of two-dimensionally targeted M-mode 
echocardiograms of the left ventricle, phonocardiogram, 
electrocardiogram (ECG), indirect carotid pulse tracings and 
blood pressure measurements were performed under base- 
line conditions. Normal subjects were premeditated with 
atropine (0.010 to 0.015 mg/kg body weight). This resulted in 
pharmacologic depression of vagal tone and allowed baseline 
data to be acquired at heart rates comparable with those 
noted in the denervated transplanted hearts. 
To assess baseline contractility and the response of the 
systemic arterial circulation to a hypertensive challenge, 
recordings were made during infusion of the alpha,-receptor 
agonist methoxamine. This drug has no direct cardiac effect 
in the doses used in the current study (12). Recordings were 
obtained every 1 to 2 min until peak systolic pressure had 
increased 30 to 60 mm Hg above baseline at which time the 
methoxamine infusion was discontinued. The desired peak 
pressor effect was obtained in all cases and lasted 2 to 5 min. 
With use of this approach, the effect of afterload changes on 
left ventricular performance could be assessed (7-10). When 
systemic arterial pressure had returned to within 5% of the 
initial value, the effect of adrenergic stimulation on left 
ventricular contractile reserve was assessed by using a 5 
pg/kg per min infusion of dobutamine. This catecholamine 
was chosen because it has beta,-, beta,- and alpha,-agonist 
effects (12-15). After 7 min of infusion, new baseline record- 
ings were performed. The methoxamine challenge was then 
repeated during the constant dobutamine infusion. 
After the methoxamine infusion was discontinued and 
peak systolic pressure had fallen to within 5% of the initial 
dobutamine value, the final part of the study was begun. 
With the dobutamine still infusing, the nonspecific beta- 
adrenergic blocking agent propranolol was given. The dose 
of the propranolol was titrated to return heart rate to the 
pre-dobutamine control value. The total dose of propranolol 
given the transplant patients and normal subjects was not 
significantly different (0.07 +- 0.01 versus 0.09 ? 0.02 mg/kg, 
respectively). The methoxamine infusion was then repeated. 
All transplant patients and normal subjects completed this 
portion of the experimental design. 
In addition, two ancillary protocols were performed: 
1) At the end of the study, the transplant patients were 
challenged with an isoproterenol infusion (26 + 4 ng/kg 
per min for 5 min) to test for adequacy of beta-adreno- 
ceptor blockade. This dose of isoproterenol was compar- 
able with the highest dose used by Yusuf et al. (16) in 
their study of adequacy of beta-blockade induced by pro- 
pranolol in patients with an orthotopic cardiac transplant. 
The increase in heart rate induced by isoproterenol in our 
patients was only 4 ? 4 beatslmin, thereby demonstrating a 
high level of effective beta-blockade. 2) One week after 
completion of the first study, the same normal subjects 
underwent a second study. At this time, the identical dose 
of propranolol was given before rather than after the initia- 
tion of the dobutamine infusion. No methoxamine was 
administered. Performance of the second study allowed a 
crossover analysis of the effects of dobutamine plus pro- 
pranolol. In addition, it eliminated the possibility that resid- 
ual alpha,-receptor activity secondary to methoxamine 
would confound the blood pressure response in the normal 
subjects. 
In summary, this protocol allowed assessment of left 
ventricular baseline contractility and contractile reserve as 
well as the effects of alpha,-, beta,- and beta,-adrenergic 
receptor stimulation with and without beta-receptor block- 
ade. This was accomplished in the transplant and normal 
subjects over a wide range of afterload conditions. Table 1 
shows the expected adrenoreceptor responses. 
Data analysis. Left ventricular end-systolic and end- 
diastolic dimensions (D,,, Ded) as well as wall thicknesses 
(h,,, bed) were measured from two-dimensionally targeted 
M-mode echocardiographic recordings as described previ- 
ously (6-8). Measurements were determined by two of the 
principal investigators (K.M.B. and A.N.) as the mean value 
of five cardiac cycles. Left ventricular mass (LVM) was 
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Table 1. Predicted Receptor Responses 
Receptor Type 
Alpha, Beta, Beta? Predictive Statement 
Methoxamine tt 0 0 Peripheral vasoconstriction 
Dobutamine t tt t Positive inotropic effect; mixed peripheral 
vasoconstriction/vasodilation 
Propranolol 0 _. __ Nonspecific beta-receptor antagonism 
Dobutamine t t C 0 Blockade of dobutamine’s positive inotropic 
propranaolol and peripheral effects resulting in 
unopposed peripheral vasoconstriction 
t = partial agonist: t t = full agonist: 0 = no effect: - - = antagonist. 
calculated from end-diastolic dimension and wall thickness 
by adapting the formula of Devereux et al. (17). Left 
ventricular end-systolic and end-diastolic volumes were es- 
timated from echocardiographic dimensions by the method 
of Teichholz et al. (18). This assumes that the visualized 
portion of the left ventricle is representative of global 
left ventricular performance, an assumption shown 
previously to be valid in the absence of significant left 
ventricular asynergy (18,19). Cardiac output was calculated 
in the standard manner from these data. Systemic vascular 
resistance was calculated as the systemic mean pressure 
(measured by the Dinamap Vital Signs Monitor) (20) times 
the conversion factor (80 dynes.cm-2.mm Hg-‘) divided by 
cardiac output. This assumes that the right atria1 mean 
pressure is small and, therefore, has little effect on the 
calculation of systemic vascular resistance in normal sub- 
jects and in transplant patients without congestive heart 
failure. 
Left ventricular percent fractional shortening f%ALl) was 
calculated in the usual manner from the echocardiogram 
whereas left ventricular ejection time (ET) was measured 
from the carotid pulse tracing. The rate-corrected mean 
velocity of left ventricular fiber shortening (Vcf,) was calcu- 
lated as (6): 
%AD %AD 
Vcf, = =- 
i i G 
ET, ’ 
where RR is the interval between adjacent R waves on the 
electrocardiogram and ET, is the heart rate corrected left 
ventricular ejection time. Calibration of the carotid pulse 
tracings was performed with assignment of systolic blood 
pressure to the peak and diastolic pressure to the nadir of the 
tracing (7,20). Linear interpolation to the level of the incisura 
was then performed to estimate end-systolic pressure (P,,) 
(6). With these data, the left ventricular end-systolic merid- 
ional wall stress (a,,) was calculated by an angiographically 
validated method (21): 
a,, = (PressureJGeometric Factor,,) 
= 0.337 (P,,) 
Statistical analysis. The relation between rate-corrected 
velocity of fiber shortening and end-systolic wall stress was 
assessed for the transplant patients and normal subjects over 
a wide range of left ventricular afterload (i.e., end-systolic 
wall stress) generated by methoxamine. Data were collected 
under baseline, dobutamine and dobutamine plus proprano- 
101 conditions. As previously reported (22), our intraob- 
server coefficients of variation for rate-corrected velocity of 
fiber shortening and end-systolic wall stress are 3.9% and 
3.8%, whereas interobserver coefficients of variation are 
7.3% and 7.6%, respectively. Under each set of conditions, 
individual rate-corrected velocity of fiber shortening-end 
systolic wall stress relation lines were generated from a 
minimum of four data points by simple linear regression 
(least squares method). Inter- and intrapatient comparisons 
were performed by assessing the relative position of the 
individual rate-corrected velocity of fiber shortening-end 
systolic wall stress relation lines as well as calculating the 
rate-corrected velocity of fiber shortening values obtained at 
equivalent levels of left ventricular afterload (i.e., end- 
systolic wall stress = 50 g/cm2). This level of end-systolic 
wall stress was chosen as the basis for comparison because 
it approximates the mean rest end-systolic wall stress for 
normal subjects (6). An unpaired t test was used for inter- 
group comparisons, whereas a paired t test was used for 
each patient to assess the effects of drug interventions. All 
values are expressed as mean values t SD. 
Results 
Baseline cardiovascular hemodynamics (Table 2). There 
were no differences between the two study groups for heart 
rate, left ventricular end-systolic wall thickness or wall 
stress, left ventricular wall mass, peak systemic pressures, 
cardiac index, overall left ventricular performance or rate- 
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Table 2. Summary of Baseline Cardiovascular Hemodynamics 
p Value 
Normal Transplant (normal versus 
Subjects Patients transplant group) 
Heart rate (beatslmin) 88 + 4 93 + 5 
LV dimensions 
End-diastolic (cm) 4.70 2 0.29 4.44 + 0.48 co.05 
End-systolic (cm) 3.17 2 0.22 2.84 2 0.32 <0.05 
LV wall thickness 
End-diastolic (cm) 1.08 ? 0.05 1.19 2 0.10 co.05 
End-systolic (cm) 1.52 + 0.10 1.73 2 0.24 
LV wall mass (g) 214 2 29 224 ? 26 
Pressures (mm Hg) 
Peak systolic 133 f 10 138 2 8 
Systemic diastolic 70 * 7 92 ? 6 <O.OOl 
Systemic mean 94 + 6 106 ? 5 10.05 
End-systolic 93 + a II6 + 5 <O.OOl 
Systemic vascular 
resistance (dynes.s.cmm5) 1248 + 239 1722 ? 375 co.05 
LV afterload 
End-systolic wall stress (g/cm*) 48 * 1 40+ 13. 
Overall LV performance 
Cardiac index (liters/minim*) 3.40 + 0.33 3.01 * 0.33 
%AD 32.5 + 2.1 36.0 f 4.0 
ET, (ms) 316 + 6 315 * 19 
Vcf, (circis) 1.03 ?z 0.06 1.14 ? 0.15 
LV contractility 
Vcf, at a,, 
= 50 &m* (circis) 1.02 + 0.03 1.05 + 0.08 
%AD = percent fractional shortening; ET, = rate-corrected ejection time; Vcf, = rate-corrected velocity of fiber 
shortening; a,, = end-systolic wall stress. 
corrected velocity of fiber shortening at an end-systolic wall 
stress of 50 g/cm2. In contrast, transplant patients had 
greater than normal systemic diastolic and mean pressures, 
left ventricular end-systolic pressure, systemic vascular re- 
sistance and left ventricular end-diastolic wall thickness than 
did the normal subjects. Left ventricular dimensions were 
smaller than normal for the transplant patients, probably 
reflecting the effects of chronically high rest heart rate. 
Effects of Pharmacologic Interventions 
Heart rate (Fig. 1). With dobutamine infusion, heart rate 
increased for both groups relative to baseline control values 
(p < 0.05 versus control for normal subjects; p < 0.001 
versus control for transplant patients). However, the in- 
crease noted for the transplant patients was significantly 
greater than that experienced by the normal subjects (p < 
0.001). With the addition of propranolol, heart rate returned 
to or slightly below baseline control values for both groups. 
Myocardial mechanics (Fig. 2 and 3). Figure 2 shows data 
from a representative transplant patient. Rate-corrected 
velocity of fiber shortening is plotted on the y axis with left 
ventricular end-systolic wall stress on the x axis. This 
relation, which incorporates afterload in its analysis, has 
been shown previously (6,23) to be independent of preload 
and heart rate and sensitive to changes in inotropic state. 
The control line was generated over a wide range of afterload 
values obtained under baseline contractile conditions. The 
infusion of dobutamine shifted the end-systolic wall stress 
Figure 1. Change from baseline heart rate induced by dobutamine 
and by dobutamine plus propranolol. The transplant patients dem- 
onstrated an exaggerated positive chronotropic response to dobu- 
tamine. CTR = control. 
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Figure 2. Plot of the relation between left ventricular (LV) rate- 
corrected velocity of fiber shortening (Vcf,) and end-systolic wall 
stress for a representative transplant patient. The increase in left 
ventricular contractility induced by dobutamine (DOB) was ablated 
by the addition of propranolol (PROP). The large arrow at the 
bottom of the figure represents the mean baseline control value (50 
g/cm’) for end-systolic wall stress for the normal subjects. 
line upward, consistent with a positive inotropic interven- 
tion. The addition of propranolol ablated the positive inotro- 
pit effect of dobutamine. By measuring rate-corrected ve- 
locity of fiber shortening values at an end-systolic wall stress 
of 50 g/cm*, which approximates the baseline value for this 
variable, it was possible to assess the left ventricular re- 
sponse to each intervention at a standardized afterload. This 
approach was used to compare baseline contractility, con- 
Figure 3. Values for rate-corrected velocity of fiber 
shortening (Vcf,) obtained at a common end-systolic 
wall stress (a,,) of 50 g/cm*. There were no differences 
between the transplant patients and normal subjects 
for baseline (CTR) contractility and contractile reserve 
as assessed by dobutamine (DOB) infusion, or the 
effects of beta-receptor antagonism with propranolol 
(PROP). 
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tractile reserve and the contractile response to beta- 
blockade for both study groups. There were no differences 
between the groups for baseline contractile state, contractile 
reserve or the effects of beta receptor antagonism with 
propranolol. Of note, comparable total amounts of propran- 
0101 were given to both study groups. 
Systemic blood pressures (Fig. 4 to 6). Dobutamine alone 
significantly increased systemic systolic and diastolic pres- 
sures relative to baseline control values (p < 0.01) (Fig. 4A). 
The addition of propranolol to the dobutamine further aug- 
mented systolic and diastolic pressures (p < 0.001 versus 
control; p < 0.01 versus dobutamine). Repeat blood pressure 
data acquired 1 week after initial study indicated that, 
whereas propranolol alone did not alter aortic pressures, the 
combination of propranolol plus dobutamine resulted in a 
marked hypertensive response (p < 0.001 versus control; 
p < 0.001 versus propranolol alone) (Fig. 4B). Whether 
propranolol was added to dobutamine or dobutamine was 
added to propranolol, the net response in normal subjects 
was a significant rise in systemic systolic and diastolic 
pressures. 
The systemic blood pressure responses to pharmacologic 
interventions differed signijcantly between the study groups 
(Fig. 5). Dobutamine increased peak systolic pressure by 
23 2 10 mm Hg in normal subjects (p < 0.01 versus control) 
and I1 2 9 mm Hg in transplant patients (p < 0.05 versus 
control; p < 0.05 normal subjects versus transplant 
patients). At the same time, systemic diastolic pressure rose 
by 15 f 12 mm Hg in normal subjects (p < 0.01 versus 
control) and only I + 6 mm Hg in transplant patients (p = 
0.39 versus control; p < 0.01 normal subjects versus trans- 
plant patients). The addition of propranolol to dobutamine in 
the normal subjects significantly raised systemic systolic 
TRANSPLANT NORMAL 
MEAN 1.05 1.29 1.04 1.02 1.29 1.02 
0.80 
SD 0.08 0.08 0.09 0.03 0.07 0.03 
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+ + 
PROP PROP 
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Figure 4. Systemic blood pressure responses to 
pharmacologic interventions in normal sub- 
jects. Regardless of the order of dobutamine 
(DOB) and propranolol (PROP) administration, 
the net response was a significant rise in aortic 
systolic and diastolic pressures. **p < 0.01 
versus control (CTR); ***p < 0.001 versus 
control; ++p < 0.01 versus dobutamine alone; 
Ooop < 0.001 versus propranolol alone. 
1 *** ++ 
??? ? ? ?
A 
/ / P / / 
/’ 
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ALONE + ALONE + 
PROP DOB 
(15 ? 9 mm Hg; p < 0.01 versus dobutamine alone) and 
diastolic (20 + 9 mm Hg; p < 0.01 versus dobutamine alone) 
pressures. In contrast, the administration of propranolol did 
not alter systemic systolic (1 k 6 mm Hg) or diastolic (1 +- 8) 
pressure in the transplant patients. 
Table 3 summarizes the changes in cardiac output, sys- 
temic vascular resistance and systemic mean pressure that 
occurred with each of the pharmacologic interventions. Of 
note, the response of the transplant patients treated with 
cyclosporine was indistinguishable from that found in the 
other transplant patients. 
To further investigate the sensitivity of the transplant 
Figure 5. Dobutamine (DOB) raised aortic systolic and diastolic 
pressures in the normal (NL) subjects but only systolic pressure 
in the transplant patients. The addition of propranolol (PROP) 
further elevated both systolic and diastolic pressures in the normal 
group without altering either pressure in the transplant group. *p < 
0.05 normal versus transplant; **p < 0.01 normal versus transplant; 
***p < 0.001 normal versus transplant. 
Figure 6. There was no age-related difference between the two 
groups of normal subjects regarding the total dose of methoxamine 
required for onset of a pressor effect. The transplant patients 
required 60% more alpha,-agonist than did either normal group. 
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Table 3. Change From Baseline Values 
p Value 
Normal Transplant (normal versus 
Subjects Patients transplant group) 
Control versus dobutamine alone 
Systemic mean pressure (mm Hg) 24 + 9* 8?7 <O.OOl 
Cardiac output (litersimin) 1.4 + 0.9* 1.6 i- 0.6* 
SVR (dynes,sxm-‘) 28 i- 140 -300 z 210* <O.Ol 
Control versus dobutamine + propranolol 
Systemic mean pressure (mm Hg) 39 A I?* 5t7 <O.OOl 
Cardiac output (litersimin) 0.1 ? 0.3 -0.3 + 0.3 
SVR (dynes,sxm-‘) 496 ? llO* 190 f 100: <O.OOl 
*p < 0.001 versus control; tp < 0.05 versus control. SVR = svstemic vascular resistance. 
patients to alpha,-receptor stimulation, the total dose of 
methoxamine required for onset of pressor effect was eval- 
uated. This was defined as the amount of methoxamine 
required to raise peak systolic pressure by 10 mm Hg above 
baseline control value. In addition to the already mentioned 
normal subjects matched for donor heart age, six additional 
normal subjects matched for recipient age were studied. 
These latter subjects were given atropine followed by 1 mg/ 
min of methoxamine (Fig. 6). There was no age-related 
difference between the two groups of normal subjects re- 
garding the total amount of methoxamine required to elicit a 
pressor effect (50 2 13 mg versus 53 + 4 mg). In contrast, the 
transplant patients required 60% more alpha,-agonist than 
did either normal group (84 ? 14 mg; p < 0.001 versus 
normal). 
Discussion 
This clinical pharmacologic study performed after cardiac 
transplantation provides evidence for normal left ventricular 
contractile and exaggerated cardiac chronotropic responses 
to beta-adrenoreceptor stimulation in association with de- 
creased peripheral vascular sensitivity to drugs with known 
smooth muscle vasoconstrictor action. The following discus- 
sion will integrate our findings with established knowledge of 
myocardial and peripheral vascular physiology to construct 
a framework for the interpretation of our data. 
Myocardial response to adrenoceptor stimulation and 
blockade. The major function of beta,-receptors in the heart 
is to mediate positive inotropic responses to an appropriate 
agonist (14,24,25). In the decompensated dilated ventricle, 
many abnormalities are present, including a decrease in 
beta,-receptor density, depletion in myocardial norepineph- 
rine stores and a reduction in isoproterenol-stimulated ade- 
nylate cyclase activity (14,24-28). These findings correspond 
well to in vitro and in vivo evidence for decreased overall left 
ventricular systolic performance (5,8,24,26,29-31). The de- 
nervated transplanted heart also has a marked reduction in 
norepinephrine stores (32). However, unlike the depletion in 
the failing ventricle, this depletion is due to interruption of 
postganglionic cardiac sympathetic nerve activity rather 
than to factors resulting from intrinsic myocardial damage or 
increased sympathetic activity with high plasma norepineph- 
rine concentrations (32). The fact that overall left ventricular 
systolic performance is generally well preserved after car- 
diac transplantation (11,33,34) suggests that normal myocar- 
dial catecholamine stores are not obligatory for normal left 
ventricular systolic function. 
In the current study, load-independent indexes of left 
ventricular contractility were assessed under baseline and 
augmented afterload conditions, during challenge with a 
catecholamine and during simultaneous administration of a 
catecholamine and a nonspecific beta receptor antagonist. In 
all cases, the transplanted heart demonstrated normal ino- 
tropic responses. Thus, the cardiac beta,-adrenergic recep- 
tors are functionally intact long term after cardiac transplan- 
tation. In contrast to the similar inotropic properties of the 
transplanted and normal hearts, the chronotropic effect of 
dobutamine was greater in the transplant patients. This 
differential response to a catecholamine’s contractile and 
heart rate effects could be caused by differences in receptor 
density or number due to chronic cardiac denervation (i.e., 
up-regulation) (14,16,25,27,35,36). Specific mechanisms that 
should be considered (14,16,25,27,37-39) include 1) sub- 
specialization of beta-adrenergic receptors in which beta,- 
receptors located in the atria are the predominant mediators 
of heart rate response, whereas beta,-receptors in the ven- 
tricle mediate positive inotropic actions; and 2) the presence 
of two separate types of beta,-receptors that independently 
mediate inotropic and chronotropic properties and undergo 
differential rates of up-regulation. 
Peripheral vascular response to adrenoceptor stimulation 
and blockade. Patients with dilated cardiomyopathy and 
symptoms of left ventricular failure have plasma norepineph- 
rine levels that are 300% to 500% above normal (l-5). 
Whereas these high levels initially act as a compensatory 
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mechanism to support the depressed inotropic state of the 
heart, they have the additional effect of increasing systemic 
vascular resistance (5,8,24). This latter action, which is 
mediated by the interaction of circulating catecholamines 
and the alpha,-adrenergic receptors in the peripheral vascu- 
lature, may lead to disadvantageous left ventricular loading 
conditions, further deterioration of ventricular performance 
and worsened congestive heart failure (8,15). It is conceiv- 
able that some of the adverse hemodynamic effects of 
peripheral vasoconstriction are blunted by down-regulation 
of alpha,-adrenergic receptors in the systemic vascular re- 
sistance vessels. This situation would be analogous to the 
down-regulation of cardiac beta,-receptors that occurs in 
patients with heart failure (14,27,28). 
Response to dobutamine alone or combined with pro- 
pranolol in normal subjects. In the current study, dobu- 
tamine, a full beta,-agonist with partial beta,- and alpha,- 
agonist effects (13,14), was used to pharmacologically probe 
adrenoceptor physiology. Dobutamine was chosen because 
its hemodynamic effects are highly dependent on the ade- 
quacy of alpha- and beta-receptor function. In the clinical 
setting, the drug’s complex hemodynamic behavior is re- 
flected in the interaction among cardiac output, systemic 
vascular resistance and systemic mean pressure. Dobu- 
tamine alone increased systemic mean pressure by 26% in 
our normal subject (p < 0.001 versus control). This pressure 
rise was due to a 23% increase in cardiac output (p < 0.001 
versus control) without a significant change in systemic 
vascular resistance. The latter finding reflects a relative 
balance between dobutamine’s peripheral vasodilator (i.e., 
beta,) and vasoconstrictor (i.e., alpha,) actions. The combi- 
nation of dobutamine plus propranolol resulted in blockade 
of dobutamine’s beta, effect leading to a return to pre- 
dobutamine cardiac output values. In addition, antagonism 
of dobutamine’s beta, action left its alpha, effect totally 
unopposed. As predicted in Table 1, this led to a marked rise 
in systemic mean pressure (p < 0.001 versus control; p < 
0.001 versus dobutamine alone). The mechanism of this 
pressure rise was peripheral vasoconstriction with an aver- 
age systemic vascular resistance value 39% above control 
(p < 0.001 versus control; p < 0.001 versus dobutamine 
alone). Thus, dobutamine plus propranolol resulted in hemo- 
dynamics that were very similar to those obtained with the 
full alpha,-agonist methoxamine. 
Response to dobutamine alone or combined with pro- 
pranolol in transplant patients. In contrast to the highly 
reproducible effects of dobutamine in normal subjects, the 
transplant patients showed only an 8% increase in systemic 
mean pressure (p < 0.001 versus normal subjects). This lack 
of a hypertensive response reflected a balance between the 
31% increase in cardiac output (p < 0.001 versus control; 
p = 0.32 versus normal subjects) due to dobutamine’s 
positive inotropic and chronotropic effects and a significant 
fall in systemic vascular resistance (p < 0.001 versus con- 
trol; p < 0.01 versus normal subjects). Unlike the situation 
with the normal subjects, dobutamine infusion in the trans- 
plant patients resulted in a demonstrable vasodilator (beta,) 
action that overwhelmed any vasoconstrictor (alpha,) effect 
of the drug. The addition of propranolol to dobutamine 
returned cardiac output to pre-dobutamine levels while 
failing to significantly alter systemic mean pressure. The 
slightly higher than control systemic vascular resistance 
values probably reflected unmasking of a weak, partial 
alpha, effect. The failure of dobutamine plus propranolol in 
the transplant patients to produce the marked vasoconstric- 
tor response noted in the normal subjects is strong evidence 
for the concept of abnormal peripheral vascular function in 
these patients. Further support of this finding was the need 
for a 60% greater total dose of methoxamine to elicit the 
onset of a pressor effect. This was true regardless of whether 
comparisons were made with donor age-matched or recipi- 
ent age-matched normal subjects. 
Etiologic mechanisms. The etiology of the abnormal pe- 
ripheral vascular response to alpha,-adrenoceptor stimula- 
tion may be multifactorial. Levine et al. (4) reported that 
mean plasma norepinephrine levels fell dramatically by 6 
months after cardiac transplantation. However, despite this 
fall, plasma norepinephrine levels at rest remained greater 
than the mean normal value in 82% of their transplant 
patients. Although plasma norepinephrine levels were not 
measured in our study, it is unlikely that such data would 
differ significantly from those of Levine et al. (4). The fact 
that the peripheral adrenergic receptors are chronically 
exposed to abnormally high concentrations of alpha,-agonist 
in patients with heart failure may be an important cause of 
the blunted peripheral vasoconstrictor response noted in our 
transplant patients. This may reflect the presence of a higher 
than normal receptor set point for agonist response, a change 
in peripheral vascular alpha receptor number or density or 
underlying structural abnormalities in the vessel wall itself. 
A second possible explanation for our transplant pa- 
tients’ abnormal systemic pressure responses is impaired 
baroreceptor function. It is known that vascular responses 
to postural changes and nitroprusside infusion are abnormal 
in patients with severe heart failure (4,40-42). Interestingly, 
long term after cardiac transplantation, Mohanty et al. (43) 
reported that the reflex increases in forearm vascular resist- 
ance and plasma norepinephrine associated with lower body 
negative pressure were smaller in transplant patients than in 
normal subjects. The impaired responses were not due to 
depression of carotid or aortic baroreceptor function be- 
cause increases in mean arterial pressure during cold pressor 
test and isometric exercise were not significantly different 
between normal and transplant groups (43). Also supporting 
the physiologically intact nature of the peripheral vascular 
baroreceptors is the fact that long term after transplantation, 
the hemodynamic responses to nitroprusside infusion are 
normal (44). The conclusion of Mohanty et al. (43) was that 
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their lower body negative pressure data probably reflected 
ventricular deafferentation as the primary etiologic factor. In 
support of this interpretation are recent findings of Scherrer 
et al. (45) obtained using microelectrode recordings of mus- 
cle sympathetic nerve activity in 12 patients after cardiac 
transplant. These authors found greatly increased basal 
sympathetic nerve discharge in spite of increased mean 
arterial pressures (108 t 3 mm Hg versus 106 2 5 mm Hg in 
our study) and suggested that this may be due to ventricular 
deafferentation. If these observations are correct, it is pos- 
sible that increased sympathetic tone in the peripheral vas- 
culature is, at least in part, the explanation for the decreased 
alpha,-agonist response noted in our transplant patients. 
Finally, the role of concomitant immunosuppressive therapy 
in the response to pharmacologic interventions in our study 
cannot be specifically addressed. However, regardless of 
whether or not the patients were taking corticosteroids or 
cyclosporine, the cardiac as well as peripheral vascular 
responses to methoxamine, dobutamine alone and dobu- 
tamine plus propranolol were the same. 
Clinical implications. The complex interaction that exists 
between the left ventricle and the peripheral vasculature 
long term after orthotopic cardiac transplantation is charac- 
terized by 1) normal myocardial beta,-mediated contractility 
and contractile reserve, 2) exaggerated myocardial beta,- or 
beta,- (or both) mediated positive chronotropic effect, and 3) 
reduced sensitivity to alpha,-receptor stimulation in the 
peripheral vasculature. The clinical model described in this 
study integrated noninvasive cardiac techniques with phar- 
macologic probes of alpha,- and beta-receptor physiology to 
assess cardiovascular function. This approach may be useful 
for assessing the physiologic changes that accompany heart 
failure as well as other functional alterations in peripheral 
vascular tone that may occur after cardiac transplantation. 
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